MelMarT Trial : A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma.

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Surgical<br/>TrialTypeSurgical
Trial

ThreePhase Three

18+Age Over 18

Skin<br/>CancersCancer LocationSkin
Cancers

Surgical | SkinMelanoma (Skin)

Trial Overview Read MoreRead more

This phase III trial is trying to determine whether a smaller surgical margin will be effective in the removal of primary cutaneous melanoma and improve patient quality of life.
 

This trial is treating patients with Cutaneous Melanoma.

This is a surgical trial.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma.

Cooperative Group

Australia and New Zealand Melanoma Trials Group (ANZMTG)

Summary

This study will determine whether there is a difference in local recurrence rates and melanoma survival rates for patients treated with either a 1cm excision margin or 2cm margin for both intermediate & high risk melanomas. Who is it for? You may be eligible to joint this study if you aged 18 years or above and have been diagnosed with a primary invasive cutaneous melanoma greater than 1mm thick. Study details Whilst patients with a primary invasive melanoma are generally recommended to undergo excision of the primary lesion with a wide margin, there is evidence that less radical margins of excision may be just as safe. Participants in this study are randomly allocated (by chance) to one of two groups. Participants in one group will undergo surgery with the 2cm excision margin, whilst participants in the other group will undergo surgery with a 1cm excision margin. Participants will be monitored for up to 60 months, in order to determine melanoma recurrence, survival rates and quality of life, and additionally, adverse events and health resource usage.

Recruiting Hospitals Read MoreRead more

Peter MacCallum Cancer Centre, Surgery
Parkville
Ms Tina Thorpe
tina.thorpe@petermac.org
03 9656 1521

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next